BIO announces workshops to be held at investor forum.
Share:
Press Release Summary:
The BIO announced the final selection of therapeutic workshops to be presented at the 7th Annual BIO Investor Forum, on Oct 29-31, 2008, in San Francisco, CA. Topics will include the latest developments in hematology as well as therapies for diseases such as fibromyalgia, osteoporosis, huntington's disease, and cystic fibrosis. The sessions will focus on upcoming regulatory approvals, clinical data reporting, FDA Advisory Committee meetings, or prospective partnering opportunities.
Original Press Release:
BIO Announces Must-See Therapeutic Workshop Topics for Seventh Annual BIO Investor Forum
Hematology, Fibromyalgia, Osteoporosis, Huntington's Disease, Cystic Fibrosis and More to be Showcased
WASHINGTON, D.C. (Thursday, September 25, 2008) - The Biotechnology Industry Organization (BIO) today announced the final selection of therapeutic workshops to be presented at the Seventh Annual BIO Investor Forum, taking place October 29-31, 2008 at the Palace Hotel in San Francisco, Calif. Experts chosen to speak on these panels represent leading clinical institutions, medical foundations, and public and private biotechnology companies.
"In order to augment the high caliber of our program, each therapeutic session is focused on near-term catalysts such as upcoming regulatory approvals, clinical data reporting, FDA Advisory Committee meetings, or prospective partnering opportunities," said Alan Eisenberg, executive vice president, Emerging Companies & Business Development at BIO. "This rigorous vetting process has resulted in a can't-miss roster of sessions."
The BIO Investor Forum's therapeutic workshops will offer a selection of topics addressing the latest developments in therapies for a wide range of diseases. A sampling of featured therapeutic workshops includes:
Hematology: Pre-ASH Primer: Hematology Heavy Hitters Discuss What's on the Horizon
Thursday, October 30, 9:00-10:45am
Moderator: Reni Benjamin, Senior Biotech Analyst, Managing Director, Rodman & Renshaw
Industry: Celator Pharmaceuticals
Clinician: Frank Giles, MD, Director of Institute for Drug Development and Chairman of the Division of Hematology and Medical Oncology, University of Texas Health Sciences Center, San Antonio
Fibromyalgia: First Things First - New Approaches to Treating Fibromyalgia are Coming into Focus but Where do Clinicians Start?
Thursday, October 30, 9:00-10:45am
Moderator: Corey Davis, Managing Director, Senior Specialty Pharmaceuticals Analyst, Natixis Bleichroeder
Advocacy: National Fibromyalgia Association
Clinician: Philip Mease, MD, Director of Seattle Rheumatology Associates, Director of the Swedish Hill Hospital Rheumatology Clinical Research Division, Clinical Professor, University of Washington, Seattle
I. Jon Russell, MD, PhD, Director of the University Clinical Research Center, Associate Professor of Medicine, University of Texas Health Science Center, San Antonio
Andrew Holman, MD, Associate Clinical Professor of Medicine, University of Washington, Seattle
Osteoporosis: Opportunity in Osteoporosis and Bone Metabolism Disorders is Spurring Pipeline Growth
Thursday, October 30, 5:00-6:10pm
Moderator: Liana Moussatos, Senior Biotechnology/Biopharmaceutical Analyst,
Pacific Growth Equities
Industry: Osteologix
Zelos Therapeutics
Clinician: Michael McClung, MD, Founding Director, Oregon Osteoporosis Center, Portland
John Bilezikian, MD, Chief of Metabolic Disease Unit, Chief of the Division of Endocrinology and Professor at the College of Physicians and Surgeons, Columbia University, New York
Huntington's Disease: A Focus on Neurodegeneration - Huntington's and Parkinson's Diseases
Friday, October 31, 9:45-11:00am
Moderator: William Ho, Senior Biotech Analyst, Bank of America Securities
Industry: Medivation
Ceregene
Clinician: Michael Geschwind, MD, PhD, Assistant Professor of Neurology, University of California, San Francisco
Cystic Fibrosis: Come up for Air! What's in the Pipeline for Cystic Fibrosis?
Friday, October 31, 9:45-11:00am
Moderator: Liana Moussatos, Senior Biotechnology/Biopharmaceutical Analyst, Pacific Growth Equities
Industry: Inspire Therapeutics
PTC Therapeutics
Clinician: Richard Moss, MD, Professor of Pediatrics, Director of Cystic Fibrosis Center, Chief of the Division of Allergy- Immunology, Stanford University
L. Terry Spencer, MD, Director of Cystic Fibrosis Center, Director of Clinical Research, Division of Respiratory Diseases, Children's Hospital Boston
To learn more about the BIO Investor Forum, including registration and program information, please visit investorforum.bio.org/. Registration is complimentary for qualified investors and credentialed members of the media.
Advance media registration is now available at www.compusystems.com/servlet/ar?evt_uid=693&site=MEDIA.
The BIO Investor Forum is a national investor conference featuring leading private and emerging public companies. The meeting attracts sophisticated healthcare venture and private equity investors, buy-side investors and research analysts. In addition, the BIO Investor Forum draws business development executives from leading global pharmaceutical and mature biotechnology companies.
Upcoming BIO Events
Intellectual Property Council Committee Fall Conference and Meeting
October 20-22, 2008
Orlando, Fla.
BIO HR Conference 2008
October 26-28, 2008
San Diego, Calif.
BIO-LES Advanced Business Development Course
October 27-29, 2008
San Francisco, Calif.
BIO Investor Forum 2008
October 29-31, 2008
San Francisco, Calif.
Advanced Business Development Course
November 14-16, 2008
Mannheim/Heidelberg, Germany
BIO-Europe 2008
November 17-19, 2008
Mannheim/Heidelberg, Germany
2009 BIO International Convention
May 18-21, 2009
Atlanta, Ga.
About BIO
BIO represents more than 1,200 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world's largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.
Contact:
Erin Reese
202-962-9235
